2026-04-17T03:52:14Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/89352025-10-24T10:42:21Zcom_2072_378070com_2072_378040col_2072_378092

Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force Sedlaczek, Oliver Kleesiek, Jens Gallagher, Ferdia Aidan Murray, Jacob Prinz, Sebastian Pérez López, Raquel Càncer - Imatgeria per ressonància magnètica ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging::Diffusion Magnetic Resonance Imaging DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética::imagen de resonancia magnética de difusión ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen Magnetic resonance imaging; Radiomics; Measurement Variability Imatges per ressonància magnètica; Radiòmica; Variabilitat de mesura Imágenes por resonancia magnética; Radiómica; Variabilidad de medida Objectives In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for noninvasive characterization of tumor viability compared to CT and RECIST. A quantification of the inter- and intraindividual variation occurring in this setting using different hardware is missing. In this study, the MRI protocol including DWI was standardized and the residual variability of measurement parameters quantified. Methods Phantom and volunteer measurements (single-shot T2w and DW-EPI) were performed at the seven CCE sites using the MR hardware produced by three different vendors. Repeated measurements were performed at the sites and across the sites including a traveling volunteer, comparing qualitative and quantitative ROI-based results including an explorative radiomics analysis. Results For DWI/ADC phantom measurements using a central post-processing algorithm, the maximum deviation could be decreased to 2%. However, there is no significant difference compared to a decentralized ADC value calculation at the respective MRI devices. In volunteers, the measurement variation in 2 repeated scans did not exceed 11% for ADC and is below 20% for single-shot T2w in systematic liver ROIs. The measurement variation between sites amounted to 20% for ADC and < 25% for single-shot T2w. Explorative radiomics classification experiments yield better results for ADC than for single-shot T2w. Conclusion Harmonization of MR acquisition and post-processing parameters results in acceptable standard deviations for MR/DW imaging. MRI could be the tool in oncologic multicenter trials to overcome the limitations of RECIST-based response evaluation. Open Access funding enabled and organized by Projekt DEAL. This study has received funding by Cancer Core Europe for the travel expenses of M. Bach traveling with the MR – Phantom between centers. 2025-10-24T10:42:21Z 2025-10-24T10:42:21Z 2025-10-24T10:42:21Z 2023-01-31T10:53:56Z 2023-01-31T10:53:56Z 2022-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/8935 European Radiology;32 https://doi.org/10.1007/s00330-022-08880-7 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Scientia